Price
No data yet.
Social Signal Score
57
5d
57
1 mentions
—
30d
57
1 mentions
—
60d
57
1 mentions
—
90d
57
1 mentions
—
news: 1
Company Profile
- Sector
- Financial Services
- Industry
- Asset Management
- Beta
- 0.83
- Country
- US
Quote
Day Range
$106.14 – $109.47
52-Week Range
$66.55 – $109.94
Volume
$7.4K
Market Cap
$43.54M
50-Day Avg
$96.55
200-Day Avg
$85.74
Prev Close
$109.90
Open
$108.26
Valuation & Ratios
P/E Ratio
—
EPS
—
P/B Ratio
—
P/S Ratio
—
Debt/Equity
—
Current Ratio
—
Dividend Yield
—
Gross Margin
—
Returns & Efficiency
Return on Equity
—
Return on Assets
—
FCF Yield
—
EV/EBITDA
—
Valuation
BBPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
107Aug 20Aug 20
Social Signal Score
57
5d
57
1 mentions
—
30d
57
1 mentions
—
60d
57
1 mentions
—
90d
57
1 mentions
—
news: 1
Mentions (1)
- Newsseekingalpha.com·5h ago·Neutral
BBP: The Biotech ETF That Filters For FDA-Approved Drugs Virtus Biotech ETF (BBP) is rated a buy for its focused exposure to FDA-approved biotech firms and strong recent outperformance. BBP's equal-weight, quarterly rebalancing strategy efficiently captures upside from breakout holdings like MRNA while reducing speculative risk. Rising sector deal activity and GLP-1 market expansion underpin a favorable outlook for BBP despite macro headwinds like higher interest rates.
View source ↗